Loading...
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca, Angela Barriuso, Jorge Kulke, M Borbath, I Lenz, H Raoul, J Meropol, N Lombard-Bohas, C Posey, J Faivre, S
Lamarca, Angela
Barriuso, Jorge
Kulke, M
Borbath, I
Lenz, H
Raoul, J
Meropol, N
Lombard-Bohas, C
Posey, J
Faivre, S
Citations
Altmetric:
Abstract
Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size decrease from baseline) are infrequent.
Affiliation
Description
Date
2017-11-21
Publisher
Collections
Files
Keywords
Type
Article
Citation
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. 2017, Br J Cancer